PULM vs NKTR vs ARWR vs AGEN vs FATE

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -100. 0% for Pulmatrix, Inc. (PULM). Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arrowhead Pharmaceuticals, Inc.

(ARWR) delivered a total return of +10. 0%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: ARWR returned +1162% versus PULM's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pulmatrix, Inc.

(PULM) is the lower-risk stock at 0. 72β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 258% more volatile than PULM relative to the S&P 500. On balance sheet safety, Fate Therapeutics, Inc. (FATE) carries a lower debt/equity ratio of 38% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -100. 0% for Pulmatrix, Inc. (PULM). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agenus Inc.

(AGEN) is the more profitable company, earning 0. 1% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARWR leads at 11. 9% versus -22. 2% for FATE. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 1552.

7% to $39. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Pulmatrix, Inc.

(PULM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PULM: -99. 7%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PULM is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; ARWR is a mid-cap high-growth stock; AGEN is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.